Difficulty Swallowing with Rexulti: Mechanism and Clinical Implications
Rexulti (brexpiprazole) causes difficulty swallowing through multiple mechanisms related to its antipsychotic properties, including extrapyramidal effects on the muscles controlling swallowing, anticholinergic effects reducing pharyngeal reflexes and esophageal motility, and sedative effects that impair coordination of the complex swallowing process 1.
Primary Mechanisms of Dysphagia
The FDA label explicitly warns that Rexulti can cause "difficulty swallowing that can cause food or liquid to get into your lungs" 1. This occurs through several pathophysiological pathways:
Extrapyramidal Motor Effects
- Bradykinesia of swallowing muscles: Brexpiprazole's dopamine D2 receptor antagonism in the striatum slows oral and pharyngeal phases of swallowing 2, 3
- Tardive dyskinesia: Can cause oro-pharyngo-esophageal dyskinesia with asynchronous, random esophageal movements 3
- Acute dystonia: May cause laryngeal or esophageal dystonia with impaired muscle contraction and upper esophageal sphincter hypertonia 3
- Dysphagia can occur as an isolated extrapyramidal symptom without other obvious neurological signs 2, 3
Anticholinergic Effects
- Reduces esophageal mobility and pharyngeal reflex 3
- Decreases coordination of the precisely timed neuromuscular sequence required for safe swallowing 4
Central Nervous System Depression
- Sedation impairs the alert participation required for the voluntary oral phase of swallowing 3
- Depression of bulbar centers reduces swallowing and gag reflexes 3
- Slows thinking and motor skills necessary for coordinated swallowing 1
Clinical Presentation and Risk Factors
Look for these specific warning signs:
- Coughing or choking while eating or drinking
- Wet or gurgly voice quality after swallowing
- Need for frequent throat clearing during meals
- Food pocketing in the mouth
- Unintentional weight loss or dehydration
- Recurrent pneumonia (aspiration) 5, 4
High-risk patients include those with:
- Concurrent muscle stiffness, tremors, or abnormal movements (common in adolescents 13-17 years) 1
- Advanced age with sarcopenia affecting swallowing muscles 4
- Polypharmacy with other medications affecting swallowing 6
- Pre-existing neurological conditions 4
Critical Safety Considerations
The most serious consequence is aspiration pneumonia from food or liquid entering the lungs 1. Many patients experience "silent aspiration" without coughing, making detection difficult 4. Additional complications include:
- Airway obstruction and choking
- Malnutrition and dehydration
- Medication nonadherence (inability to swallow pills) 2
Management Algorithm
When dysphagia is suspected:
Immediate assessment: Question patient and caregivers specifically about coughing during meals, fear of choking, and perceived swallowing difficulties 5
Physical examination: Check for dysarthria, dysphonia, weak voluntary cough, and other extrapyramidal signs 5
Consider medication modification:
- Reduce Rexulti dose
- Switch to alternative antipsychotic with lower EPS risk (e.g., aripiprazole showed improvement in one case) 2
- Avoid discontinuing abruptly without psychiatric consultation
Refer for formal swallowing evaluation if symptoms persist, including videofluoroscopic swallowing evaluation (VSE) or fiberoptic endoscopic evaluation of swallowing (FEES) 5
Nutritional assessment and chest radiograph to evaluate for aspiration complications 5
Important Caveats
Research shows that antipsychotic-induced dysphagia affects 21.9-69.5% of patients taking these medications 7, yet it remains underrecognized because patients rarely spontaneously report swallowing difficulties 2, 3. Proactively screen all patients on Rexulti for dysphagia symptoms at each visit, particularly when initiating therapy or increasing doses. The symptom can occur even without other obvious extrapyramidal signs, making it easy to miss 2, 3.
While the FDA label lists dysphagia as a known side effect 1, the specific prevalence with brexpiprazole is not well-established in the literature, though the mechanism is consistent with other second-generation antipsychotics where dysphagia has been documented 2, 7.